Taking people in Németország1. fázis
Long-term follow-up of patients treated with GD2IL18CART
Key facts
- Where
- Erlangen, Essen, Muenster és Tuebingen, NémetországSee the 4 sites
- Phase
- 1. fázis
Where in Németország
- Universitaetsklinikum Erlangen AöRErlangen, NémetországTaking people
- Universitaetsklinikum Essen (AoR)Essen, NémetországTaking people
- Universitaet MuensterMuenster, NémetországTaking people
- Universitaetsklinikum Tuebingen AöRTuebingen, NémetországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitaet Muenster
- Trial code
- EU 2025-521497-34-00
- Record updated
- 2026. szeptember 23.
- Original description
To evaluate long-term safety after treatment with GD2IL18CARTRead full original descriptionShow less
To evaluate long-term safety after treatment with GD2IL18CART
Inclusion: Patient underwent treatment with GD2IL18CART in the primary trial prior to enrollment into long-term follow-up; Patient and/or caregivers have provided informed consent at any time prior to the first trial-specific assessment.
Exclusion: No exclusion criteria are defined for this long-term follow-up trial.